Gsa Capital Partners LLP Blueprint Medicines Corp Transaction History
Gsa Capital Partners LLP
- $1.11 Billion
- Q1 2025
A detailed history of Gsa Capital Partners LLP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Gsa Capital Partners LLP holds 3,688 shares of BPMC stock, worth $351,466. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,688Holding current value
$351,466% of portfolio
0.03%Shares
11 transactions
Others Institutions Holding BPMC
# of Institutions
391Shares Held
68.5MCall Options Held
1.54MPut Options Held
1.08M-
Black Rock Inc. New York, NY6.65MShares$633 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$633 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.42MShares$516 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$367 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$293 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.69B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...